The pharmaceutical and biological sector has been heavily sold off by the main funds in the past three days

Clinical CRO Tigermed: The ‘Small and Beautiful’

In this race of pharmaceutical R&D outsourcing segment, WuXi AppTec, Pharmaron, Tigermed and Asychem are some of the major names – but which has a truly winning side?

China's April CPI Rises Moderately to 1.2%; PPI Surges Significantly Driven by International Commodities and Computing Power Demand

On May 11, the National Bureau of Statistics of China released data showing that in April 2026, the national Consumer Price Index (CPI) rose by 1.2% year-on-year, an increase of 0.2 percentage points from the previous month, with the month-on-month figure turning from a decline to a rise. The moderate recovery of the CPI was primarily driven by the dual impact of surging energy prices and an explosion in travel demand during holidays.

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

CRO Giant Tigermed’s 1H 2020 Net Profits Up 98%

Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.

WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell

According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index.  It has been considered a top holding by many MSCI China indexes for some time.